 "Suven Pharma reports Q2 net profit decline of 20.35% to Rs 74.07 crore")
Drug firm Suven Pharmaceuticals on Friday reported a 20.35 per cent decline in its consolidated net profit at Rs 74.07 crore for the quarter ended September 30, 2020.
The company had posted a net profit of Rs 93 crore for the corresponding period of the previous fiscal, Suven Pharmaceuticals said in a filing to BSE.
Consolidated total income of the company stood at Rs 237.74 crore for the quarter under consideration. It was Rs 278.37 crore for the same period year ago, it added.
"The board has allotted the bonus shares at 1:1 ratio in its meeting held on September 29, 2020," the filing said.
The board has approved capital expenditure (capex) plan of Rs 600 crore keeping in view of the proposed increase in capacity in Pashamylaram facility, replacement and modernization of production blocks in Suryapet facility, relocation of R&D facilities from Jeedimetla and acquisition of new technologies, it added.
Shares of Suven Pharmaceuticals were trading at Rs 308.70 per scrip on BSE, down 8.86 per cent from its previous close.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app